LTRN
Lantern Pharma Inc
NASDAQ: LTRN · HEALTHCARE · BIOTECHNOLOGY
$2.05
+3.54% today
Updated 2026-04-30
Market cap
$27.69M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.57
Dividend yield
—
52W range
$1 – $6
Volume
0.7M
WallStSmart proprietary scores
20
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.0
Quality
C+3.0
Profitability
D5.0
Valuation
C+—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$20.00
+875.61%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
Insufficient data
Risks
- Thin margins at 0.00%
- Negative free cash flow $-2.79M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-14.26M | $-15.96M | $-20.78M | $-17.12M | $-4.07M |
| EPS | — | — | — | — | $-1.57 |
| Free cash flow | $-12.80M | $-14.37M | $-17.83M | $-15.68B | $-2.79M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Lantern Pharma Inc trades at $2.05. Our Smart Value Score of 20/100 indicates the stock is weak.
Frequently asked questions
What is Lantern Pharma Inc's stock price?
Lantern Pharma Inc (LTRN) trades at $2.05.
Is Lantern Pharma Inc overvalued?
Smart Value Score 20/100 (Grade F, Strong Sell).
What is the price target of Lantern Pharma Inc (LTRN)?
The analyst target price is $20.00, representing +875.6% upside from the current price of $2.05.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-123.50%
Beta1.75
50D MA$2.35
200D MA$3.46
Shares out0.01B
Float0.01B
Short ratio—
Avg volume0.7M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—